{"id":1053,"date":"2026-02-08T06:37:42","date_gmt":"2026-02-08T06:37:42","guid":{"rendered":"https:\/\/foreignnewstoday.com\/?p=1053"},"modified":"2026-02-08T06:37:42","modified_gmt":"2026-02-08T06:37:42","slug":"hims-hers-pulls-copycat-weight-loss-pill-after-legal-threats","status":"publish","type":"post","link":"https:\/\/foreignnewstoday.com\/?p=1053","title":{"rendered":"Hims &#038; Hers pulls copycat weight-loss pill after legal threats"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div id=\"RegularArticle-ArticleBody-5\" data-module=\"ArticleBody\" data-test=\"articleBody-2\" data-analytics=\"RegularArticle-articleBody-5-2\"><span class=\"HighlightShare-hidden\" style=\"top:0;left:0\"\/><\/p>\n<div class=\"InlineImage-imageEmbed\" id=\"ArticleBody-InlineImage-108262492\" data-test=\"InlineImage\">\n<div class=\"InlineImage-wrapper\">\n<div>\n<p>Piotr Swat | Lightrocket | Getty Images<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p><span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-1\"><a href=\"https:\/\/www.cnbc.com\/quotes\/HIMS\/\">Hims &amp; Hers<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span> on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and <a href=\"https:\/\/www.cnbc.com\/2026\/02\/06\/wegovy-hims-hers-stock-novo-nordisk-pill-latest.html\">threats of legal action<\/a> earlier this week.<\/p>\n<p>&#8220;Since launching the compounded semaglutide pill on our platform, we&#8217;ve had constructive conversations with stakeholders across the industry,&#8221; the telehealth provider <a href=\"https:\/\/x.com\/himsherscomms\/status\/2020207947645911214?s=46\" target=\"_blank\">posted<\/a> on social media. &#8220;As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.&#8221;<\/p>\n<p>Hims &amp; Hers had previously said it planned to create a cheaper, copycat version of pharmaceutical giant <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-4\"><a href=\"https:\/\/www.cnbc.com\/quotes\/NVO\/\">Novo Nordisk&#8217;s<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span> Wegovy weight-loss pill. That treatment \u2014 featuring Wegovy&#8217;s active ingredient, semaglutide \u2014 was set to launch for as little as $49 for the first month. Novo&#8217;s pill sells for roughly $100 more.<\/p>\n<p>Novo on Thursday <a href=\"https:\/\/www.cnbc.com\/2026\/02\/05\/eli-lilly-novo-nordisk-stock-wegovy-hims-hers-pill.html\">threatened legal action<\/a> against Hims for what it called &#8220;illegal mass compounding,&#8221; adding that the company planned to take legal and regulatory action. <\/p>\n<p>&#8220;This is another example of Hims &amp; Hers&#8217; historic behaviour of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs,&#8221; Novo said in a <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916489\" target=\"_blank\">statement<\/a> at the time.<\/p>\n<p>On Friday, the U.S. Food and Drug Administration weighed in, <a href=\"https:\/\/www.cnbc.com\/2026\/02\/06\/fda-to-restrict-glp-1-ingredients-used-in-nonapproved-compounded-drugs.html\">announcing<\/a> it planned to take legal action against Hims &amp; Hers for the pill, including restricting access to the ingredients and referring the company to the Department of Justice.<\/p>\n<p>In response, Hims on Saturday said it &#8220;has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law.&#8221;<\/p>\n<p>The move comes as the company plans to <a href=\"https:\/\/news.hims.com\/newsroom\/the-health-gap-is-a-wealth-gap-that-stops-next-sunday\" target=\"_blank\">run an advertisement<\/a> during Super Bowl 60 on Sunday. The ad features rapper Common voicing the message that &#8220;America&#8217;s wealth gap has turned into a health gap.&#8221; <\/p>\n<p>Hims previously said it expects the ad to &#8220;ruffle some feathers.&#8221;<\/p>\n<\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.cnbc.com\/2026\/02\/07\/hims-hers-weight-loss-pill.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piotr Swat | Lightrocket | Getty Images Hims &amp; Hers on Saturday said that it will pull its copycat weight-loss pill off the market after sparking&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[28],"tags":[],"class_list":["post-1053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-news"],"_links":{"self":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts\/1053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1053"}],"version-history":[{"count":0,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts\/1053\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/media\/1054"}],"wp:attachment":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}